ArticleTherapeutic advances in medical oncology2022

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.

Bernadette de Rauglaudre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.